Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sulfurous Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.30 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL11332125 | 1.00 | CA1 (0.30) | CA1CA2 | |
| Sulfurous Acid SCHEMBL1000 | 1.00 | — | — | |
| Sulfurous Acid SCHEMBL6339977 | 1.00 | CA1 (0.30) | CA1CA2 | |
| Sulfurous Acid SCHEMBL33389 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL33388 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL3884263 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL8003768 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL11437490 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL916642 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL5047648 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217243-A1 | A METHOD FOR MANUFACTURING MEDIUM AND HIGH-DENSITY FIBERBOARD WITH SOY COMPONENTS | CARGILL, INCORPORATED (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2026104886-A1 | METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY | 유엔케이코리아 주식회사 | 2026-05-21 | — | — | WO | disclosed |
| US-12622880-B2 | Therapeutic system for the topical, transdermal and transcutaneous application of carbon monoxide | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2026-05-12 | — | — | US | disclosed |
| US-12569448-B2 | Membrane-based two component therapeutic gas release system for oral administration | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2026-03-10 | — | — | US | disclosed |
| WO-2025242583-A1 | NOVEL FORMULATION COMPRISING ELINZANETANT IN A SOLID DISPERSION | BAYER CONSUMER CARE AG (CH) | 2025-11-27 | — | — | WO | disclosed |
| EP-2822653-B1 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2024-06-19 | — | — | EP | disclosed |
| CN-115850123-B | Preparation method of 2, 4-dichloroaniline/hydrazine | 山东潍坊润丰化工股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240122862-A1 | MEMBRANE-BASED TWO COMPONENT THERAPEUTIC GAS RELEASE SYSTEM FOR ORAL ADMINISTRATION | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-117867481-A | High-stability cyanide-free electroless reduced gold plating solution | 江苏矽智半导体科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230112937-A1 | THERAPEUTIC SYSTEM FOR THE TOPIC, TRANSDERMAL AND TRANSCUTANEOUS APPLICATION OF CARBON MONOXIDE | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-115850123-A | Preparation method of 2, 4-dichloroaniline/hydrazine | 山东潍坊润丰化工股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4117621-A1 | THERAPEUTIC SYSTEM FOR THE TOPIC, TRANSDERMAL AND TRANSCUTANEOUS APPLICATION OF CARBON MONOXIDE | Julius-Maximilians-Universitaet Wuerzburg (DE) | 2023-01-18 | — | — | EP | disclosed |
| EP-2651991-B2 | USE OF A POLYMER OF ACRYLIC ACID AS DISPERSANT IN MINERAL PROCESSING | BASF SE (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4045006-A1 | MEMBRANE-BASED TWO COMPONENT THERAPEUTIC GAS RELEASE SYSTEM FOR ORAL ADMINISTRATION | Julius-Maximilians-Universität Würzburg (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-8871299-B2 | Solid particles having a silicate coating | GIESECKE & DEVRIENT GMBH (DE) | 2014-10-28 | — | — | US | disclosed |
| US-20120237668-A1 | SOLID PARTICLES HAVING A SILICATE COATING | GIESECKE & DEVRIENT GMBH (DE) | 2012-09-20 | — | — | US | disclosed |
| US-5089089-A | Mixing tank, retention tank, thichening press, and liquid recovery | BEAR ISLAND PAPER COMPANY (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112937-A1 | THERAPEUTIC SYSTEM FOR THE TOPIC, TRANSDERMAL AND TRANSCUTANEOUS APPLICATION OF CARBON MONOXIDE | S100B, GJB2, COL2A1 | CA1 399/4885CA2 209/4885 |
| US-20240122862-A1 | MEMBRANE-BASED TWO COMPONENT THERAPEUTIC GAS RELEASE SYSTEM FOR ORAL ADMINISTRATION | VIP, SCAMP2, GSDMD | CA1 947/4885CA2 764/4885 |
| US-12569448-B2 | Membrane-based two component therapeutic gas release system for oral administration | GSDMD, EPCAM, TAS2R10 | CA1 3215/4885CA2 2453/4885 |
| US-12622880-B2 | Therapeutic system for the topical, transdermal and transcutaneous application of carbon monoxide | COL2A1, COL1A1, MB | CA1 1730/4885CA2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.